Cargando…
Sex‐Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD
BACKGROUND: Despite high female prevalence of peripheral artery disease (PAD), little is known about sex‐based outcomes after lower extremity revascularization (LER) for symptomatic PAD. The effects of rivaroxaban according to sex following LER have not been fully reported. METHODS AND RESULTS: In V...
Autores principales: | Hess, Connie N., Baumgartner, Iris, Anand, Sonia S., Nehler, Mark R., Patel, Manesh R., Debus, E. Sebastian, Szarek, Michael, Capell, Warren, Muehlhofer, Eva, Berkowitz, Scott D., Haskell, Lloyd P., Bauersachs, Rupert M., Bonaca, Marc P., Hsia, Judith |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238670/ https://www.ncbi.nlm.nih.gov/pubmed/35699170 http://dx.doi.org/10.1161/JAHA.121.024655 |
Ejemplares similares
-
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone
por: Berkowitz, Scott D., et al.
Publicado: (2022) -
Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a “CASPAR like” outcome from VOYAGER PAD
por: Bonaca, Marc P., et al.
Publicado: (2022) -
Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization
por: Hess, Connie N., et al.
Publicado: (2022) -
Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease
por: Szarek, Michael, et al.
Publicado: (2022) -
Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial
por: Hess, Connie N., et al.
Publicado: (2022)